| |
|
|
|
Terrapinn Ltd., Royal Horseguards Hotel, London, UK
13-15 May 2008
Monday 13 May 2008 - Briefing Day: Stem cells in drug discovery and toxicity - Developing consortia to negotiate funding, research and legislative challenges
- Stem cells as tools in drug discovery
- Stem cell usage in toxicology
- Novel strategies for target discovery
Wednesday 14 May 2008 - Conference Day 1 - Stem cell development: emerging into a competitive marketplace
- Funding and operation: securing investment for stem cell businesses
- Expansion of clinical automation processes
- Multi-phase clinical trials in therapeutic stem cell applications
Thursday 15 May 2008 - Conference Day 2 - Motion towards therapeutic stem cell research
- Developments within the regulatory, IP and reimbursement landscape
- Contract manufacturing: scaling-up and developing a profitable business model for post-clinical operation
- The necessity for an international industry association for regenerative medicine
|
|
|
|
|
|
|
|
Organized by:
|
|
Terrapinn Ltd. |
|
|
Invited Speakers:
|
|
Dr Tim Allsopp, CSO, Stem Cell Sciences Dr Mark Bale, Deputy Director of Scientific Development & Bioethics, Department of Health Dr Petter Björquist, Senior Principal Scientist, Cellartis Mr Gregory A Bonfiglio, Managing Director and Partner, Proteus Venture Partners Professor Oliver Brüstle, Director, Institute of Reconstructive Neurobiology, LIFE & BRAIN Center Dr Gabriela Cezar, Assistant Professor, University of Wisconsin-Madison Dr Yen Choo, CEO, Plasticell Professor Ian Cotgreave, Director of Molecular Toxicology and safety assessment, AstraZeneca Dr Stuart Craig, Chief Technical Officer and Vice President, Progenitor Cell Therapy Dr Ivor Elrifi, Co-chair Intellectual Property Section, Mintz Levin Dr Michael Hunt, CEO, ReNeuron Mr Hugh Ilyine, Vice-President and COO, Stem Cell Sciences Dr Paul Kemp, CEO, Intercytex Mr James Lawford-Davies, Solicitor, Clifford Chance Dr Alan Lewis, President and CEO, Novocell Dr Nicolas L'Heureux, CSO, Cytograft Tissue Engineering Inc. Dr Mats Lundvall, CEO, Cellartis Dr Geoff Mackay, President and CEO, Organogenesis Inc Dr Chris Mason, Director, Regenerative Medicine Bioprocessing Unit, University College London Dr John McNeish, Senior Director, Pfizer Global R&D Dr Randal Mills, CEO, Osiris Dr Stephen Minger, Director, Stem Cell Biology Laboratory, King's College London Dr Gail Naughton, CEO, Histogen Dr Thomas Okarma, President and CEO, Geron Dr Ajan Reginald, Global Director of Business Development, Roche Dr Alan Russell, Director, McGowen Institute for Regenerative Medicine Dr Elyse Seltzer, CMO/ Vice President of Clinical Development and Medical Affairs, Tengion Dr Michael Siani-Rose, President and Founder, Theregen Mr Bernard Siegel, Executive Director, Genetics Policy Institute Mr David Smith, Head of Cell Therapy, Lonza R&D Dr Ralph Snodgrass, President and CEO, Vistagen Therapeutics Inc Dr Alan Trounson, President, California Institute for Regenerative Medicine Dr Michael West, CEO, BioTime, Inc Mr Gareth Williams, Solicitor, MARKS & CLERK
| |
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
N/A
|
|
|
|
|
|
|
|
Registration:
|
|
3 easy ways to register:
|
|
|
E-mail:
|
|
caroline.thoresen@terrapinn.com
|
|
|
|
|
|
|
|
|